GeneDx Holdings (WGS) Cash & Equivalents (2020 - 2026)

GeneDx Holdings (WGS) has reported Cash & Equivalents for 7 consecutive years, with $60.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 18.62% year-over-year to $60.3 million in Q2 2026; TTM through Jun 2026 was $60.3 million, a 18.62% decrease from a year earlier, with the FY2025 full-year figure at $105.0 million, up 23.22% from the prior year.
• Cash & Equivalents was $60.3 million for Q2 2026 at GeneDx Holdings, down from $93.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $315.0 million in Q1 2022 and troughed at $56.1 million in Q2 2024.
• A 5-year average of $126.3 million and a median of $97.8 million in 2023 frame the typical range for Cash & Equivalents.
• The widest YoY moves for Cash & Equivalents: up 974.1% in 2022, down 69.06% in 2022.
• Over 5 years, Cash & Equivalents stood at $123.9 million in 2022, then slipped by 19.57% to $99.7 million in 2023, then fell by 14.52% to $85.2 million in 2024, then grew by 23.22% to $105.0 million in 2025, then tumbled by 42.55% to $60.3 million in 2026.
• The last three Cash & Equivalents figures came in at $60.3 million (Q2 2026), $93.9 million (Q1 2026), and $105.0 million (Q4 2025), per Business Quant data.